The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences, in collaboration ...

Defence Secretary Pete Hegseth has endorsed a Christian pastor who wrote that “unsubmissive” women are a “truly destructive ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

These were among the concerns of a recent regulatory inspection of a key, but historically troubled, manufacturing plant that ...

We write as members of the international medical community to call upon the Israeli Medical Association (IMA) to uphold its commitment to ethical principles by supporting independent international ...

Fidelity Enhanced Large Cap Core is a growth-focused fund with tech exposure, balanced strategy, and strong risk-adjusted ...

Michael R. Jackson's hit Broadway musical, A Strange Loop, was in part inspired by the crass way HIV was treated by Tyler ...

At Martha’s Vineyard, Touch Talks Wellness and BlackDoctor.org joined forces to host an urgent and deeply personal conversation on cancer disparities in the Black community. Powered by partnerships ...